| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $4,515 | 1 | 2 |
Sells | $146,249,054 | 50 | 98 |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 1 | $4,515 | 4 | $18.2M | $-18.19M |
| Zane Ellen M | director | 0 | $0 | 1 | $1.42M | $-1.42M |
| Woodworth Emily | SVP, Global Controller and CAO | 0 | $0 | 4 | $1.92M | $-1.92M |
| Brown Vance R | SVP, GC and Corp. Secretary | 0 | $0 | 4 | $1.96M | $-1.96M |
| LUDWIG EDWARD J | director | 0 | $0 | 3 | $2.13M | $-2.13M |
| Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 0 | $0 | 5 | $2.94M | $-2.94M |
| Carruthers Wendy | EVP, Human Resources | 0 | $0 | 6 | $3.44M | $-3.44M |
| Sorenson John Bradley | EVP, Global Operations | 0 | $0 | 9 | $5.85M | $-5.85M |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 0 | $0 | 4 | $5.89M | $-5.89M |
| Brennan Daniel J. | EVP and CFO | 0 | $0 | 4 | $11.38M | $-11.38M |
| Mahoney Michael F | Chairman, President & CEO | 0 | $0 | 6 | $91.13M | $-91.13M |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Over the last 12 months, insiders at Boston Scientific Corporation have bought $4,515 and sold $146.25M worth of Boston Scientific Corporation stock.
On average, over the past 5 years, insiders at Boston Scientific Corporation have bought $1.05M and sold $89.66M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) — $4,515.
The last purchase of 50 shares for transaction amount of $4,515 was made by Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) on 2024‑12‑03.
| 2025-06-04 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 56,372 0.0038% | $102.88 | $5.8M | -2.12% | |
| 2025-06-02 | Sale | Mahoney Michael F | Chairman, President & CEO | 164,443 0.0111% | $103.69 | $17.05M | -2.15% | |
| 2025-05-29 | Sale | LUDWIG EDWARD J | director | 4,000 0.0003% | $104.59 | $418,368 | -2.46% | |
| 2025-05-21 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 4,826 0.0003% | $106.42 | $513,583 | -3.09% | |
| 2025-05-05 | Sale | Sorenson John Bradley | EVP, Global Operations | 4,572 0.0003% | $104.54 | $477,957 | -1.36% | |
| 2025-05-01 | Sale | Mahoney Michael F | Chairman, President & CEO | 164,443 0.011% | $102.48 | $16.85M | +0.89% | |
| 2025-05-01 | Sale | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 17,314 0.0012% | $102.06 | $1.77M | +0.89% | |
| 2025-04-21 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 4,826 0.0003% | $95.09 | $458,904 | +9.90% | |
| 2025-04-01 | Sale | Mahoney Michael F | Chairman, President & CEO | 164,442 0.011% | $100.01 | $16.45M | +1.00% | |
| 2025-03-21 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 4,826 0.0003% | $100.85 | $486,702 | +1.46% | |
| 2025-03-04 | Sale | Woodworth Emily | SVP, Global Controller and CAO | 482 <0.0001% | $104.63 | $50,432 | -2.14% | |
| 2025-03-03 | Sale | Woodworth Emily | SVP, Global Controller and CAO | 7,149 0.0005% | $104.97 | $750,465 | -3.20% | |
| 2025-02-28 | Sale | Woodworth Emily | SVP, Global Controller and CAO | 9,887 0.0007% | $101.13 | $999,872 | -2.14% | |
| 2025-02-25 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 2,688 0.0002% | $104.00 | $279,552 | +0.83% | |
| 2025-02-24 | Sale | Zane Ellen M | director | 13,586 0.0009% | $104.23 | $1.42M | -2.73% | |
| 2025-02-24 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 4,675 0.0003% | $104.25 | $487,369 | -2.73% | |
| 2025-02-21 | Sale | Brown Vance R | SVP, GC and Corp. Secretary | 4,826 0.0003% | $104.64 | $504,993 | -2.80% | |
| 2025-02-19 | Sale | Brennan Daniel J. | EVP and CFO | 67,333 0.0046% | $105.24 | $7.09M | -3.83% | |
| 2025-02-19 | Sale | Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 1,510 0.0001% | $105.35 | $159,079 | -3.83% | |
| 2025-02-19 | Sale | Sorenson John Bradley | EVP, Global Operations | 3,303 0.0002% | $105.19 | $347,443 | -3.83% |
| Mahoney Michael F | Chairman, President & CEO | 1476882 0.0998% | $149.71M | 2 | 28 | +37.05% |
| Brennan Daniel J. | EVP and CFO | 225808 0.0153% | $22.89M | 0 | 27 | |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 178342 0.0121% | $18.08M | 1 | 21 | |
| Zane Ellen M | director | 34944 0.0024% | $3.54M | 0 | 1 | |
| Brown Vance R | SVP, GC and Corp. Secretary | 31367 0.0021% | $3.18M | 0 | 7 | |
| Carruthers Wendy | EVP, Human Resources | 29308 0.002% | $2.97M | 0 | 46 | |
| Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 25766 0.0017% | $2.61M | 0 | 48 | |
| LUDWIG EDWARD J | director | 22479 0.0015% | $2.28M | 1 | 5 | +26.95% |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 22235 0.0015% | $2.25M | 0 | 20 | |
| Sorenson John Bradley | EVP, Global Operations | 18705 0.0013% | $1.9M | 0 | 35 | |
| Woodworth Emily | SVP, Global Controller and CAO | 432 0% | $43,791.84 | 0 | 4 | |
| NICHOLAS PETER M | director | 3531021 0.2387% | $357.94M | 0 | 249 | |
| ABELE JOHN E | Director Emeritus | 500000 0.0338% | $50.69M | 5 | 212 | +7.41% |
| Bose Supratim | EVP & President, Asia-Pacific | 320301 0.0217% | $32.47M | 0 | 2 | |
| BEST LAWRENCE C | EVP | 232189 0.0157% | $23.54M | 1 | 24 | <0.0001% |
| NICHOLAS NJ JR | director | 225000 0.0152% | $22.81M | 20 | 1 | +2.99% |
| Nanavaty Maulik | SVP & Pres, Neuromodulation | 166869 0.0113% | $16.92M | 0 | 22 | |
| Pratt Timothy A. | EVP, GC & Chief Admin Officer | 154681 0.0105% | $15.68M | 0 | 32 | |
| ELLIOTT JOHN RAYMOND | director | 118264 0.008% | $11.99M | 1 | 0 | <0.0001% |
| Kucheman William | Chief Executive Officer | 112525 0.0076% | $11.41M | 3 | 1 | +27.04% |
| Lance Jean Fitterer | SVP, Asst GC, Bus & Regions | 97504 0.0066% | $9.88M | 0 | 10 | |
| Phalen Michael P. | EVP & President, MedSurg | 97910 0.0066% | $9.93M | 0 | 38 | |
| MARIO ERNEST | director | 86032 0.0058% | $8.72M | 22 | 18 | +4.51% |
| Ballinger Kevin J. | EVP & Pres, Interven Cardio | 80085 0.0054% | $8.12M | 0 | 25 | |
| Wang Xin Warren | SVP and Pres, Asia Pacific | 75469 0.0051% | $7.65M | 0 | 4 | |
| Dawkins Keith D | EVP, Global Chief Med. Off. | 68165 0.0046% | $6.91M | 0 | 4 | |
| PEPPER JOHN E | director | 58807 0.004% | $5.96M | 3 | 0 | <0.0001% |
| Pucel Kenneth | EVP, Glob Ops, Qual & Tech | 59000 0.004% | $5.98M | 0 | 1 | |
| TOBIN JAMES R | President and CEO | 50000 0.0034% | $5.07M | 0 | 2 | |
| LAVIOLETTE PAUL A | COO | 49422 0.0033% | $5.01M | 0 | 5 | |
| MCCONNELL WILLIAM F JR | SVP, Administration CRM | 48949 0.0033% | $4.96M | 0 | 2 | |
| Prange Karen | SVP&Pres, Uro & Pelvic Health | 38395 0.0026% | $3.89M | 0 | 6 | |
| MACLEAN ROBERT G | SVP, HR | 36502 0.0025% | $3.7M | 0 | 10 | |
| Monson Jonathan | SVP, Global Controller and CAO | 34868 0.0024% | $3.53M | 0 | 5 | |
| SANDMAN PAUL W | EVP and General Counsel | 33866 0.0023% | $3.43M | 0 | 4 | |
| Sununu John E | director | 32265 0.0022% | $3.27M | 3 | 4 | +4.31% |
| Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 31422 0.0021% | $3.19M | 0 | 13 | |
| Bartlett Katharine T | director | 29708 0.002% | $3.01M | 1 | 0 | +4.24% |
| Meredith Ian T | EVP Global Chief Med Officer | 28082 0.0019% | $2.85M | 0 | 2 | |
| Connors Nelda J | director | 27246 0.0018% | $2.76M | 1 | 4 | <0.0001% |
| WICHMANN DAVID S | director | 25000 0.0017% | $2.53M | 1 | 0 | +0.3% |
| Mackey Edward F | EVP, Operations | 23722 0.0016% | $2.4M | 0 | 3 | |
| Eddy Jodi Euerle | SVP, Chief Info & Digital Off. | 23263 0.0016% | $2.36M | 0 | 8 | |
| Scanlon Meghan | SVP,Pres,Urology Pelvic Health | 19142 0.0013% | $1.94M | 0 | 2 | |
| FLEISHMAN JOEL LAWRENCE | director | 18250 0.0012% | $1.85M | 1 | 0 | +1.14% |
| Olson Scott | SVP & Pres, CRM, Diagnostics | 14518 0.001% | $1.47M | 0 | 6 | |
| BURNS URSULA M | director | 13500 0.0009% | $1.37M | 4 | 0 | <0.0001% |
| Ralls-Morrison Desiree | SVP, GC and Corp Secretary | 11450 0.0008% | $1.16M | 0 | 3 | |
| TAYLOR JAMES H JR | Sr. VP, Operations | 9360 0.0006% | $948,823.20 | 0 | 4 | |
| MORECI STEPHEN F | SVP, Global Sales Operations | 7216 0.0005% | $731,485.92 | 1 | 7 | <0.0001% |
| REINHARDT UWE E | director | 5000 0.0003% | $506,850.00 | 3 | 1 | <0.0001% |
| Goodman Jeffrey H | SVP, International | 5000 0.0003% | $506,850.00 | 2 | 0 | <0.0001% |
| FOX MARYE ANNE | director | 3305 0.0002% | $335,027.85 | 1 | 0 | +18.63% |
| GROVES RAY J | director | 1000 0.0001% | $101,370.00 | 3 | 0 | <0.0001% |
| BARTELL MARK C | SVP Global Sales/Mkt CRM | 1812 0.0001% | $183,682.44 | 0 | 1 | |
| Burns Brian R | EVP - Global Quality & Reg Aff | 1289 0.0001% | $130,665.93 | 0 | 1 | |
| JOHNSON KRISTINA M | director | 0 0% | $0 | 0 | 3 | |
| DEPARLE NANCY ANN | director | 0 0% | $0 | 0 | 2 | |
| COLEN FRED | EVP & Chief Technology Officer | 0 0% | $0 | 0 | 18 | |
| CAPELLO JEFFREY D | EVP & Chief Financial Officer | 447 0% | $45,312.39 | 0 | 5 | |
| FUJIMORI YOSHIAKI | director | 0 0% | $0 | 0 | 1 | |
| Russell Mary E | SVP and CMO | 0 0% | $0 | 0 | 2 | |
| Dockendorff Charles J | director | 0 0% | $0 | 1 | 2 | +35.4% |
| Pedersen John B. | Pres, Uro & Women's Health | 0 0% | $0 | 0 | 3 | |
| Pierce David A | EVP Pres MedSurg | 0 0% | $0 | 0 | 88 |
| Increased Positions | 903 | +61.55% | 88M | +6.57% |
| Decreased Positions | 639 | -43.56% | 70M | -5.22% |
| New Positions | 238 | New | 18M | New |
| Sold Out Positions | 82 | Sold Out | 3M | Sold Out |
| Total Postitions | 1,731 | +18% | 1B | +1.35% |
| Blackrock, Inc. | $14.87M | 9.58% | 141.67M | +3M | +1.9% | 2025-03-31 |
| Vanguard Group Inc | $13.94M | 8.99% | 132.89M | +2M | +1.22% | 2024-12-31 |
| Fmr Llc | $13.9M | 8.96% | 132.44M | -3M | -2.04% | 2024-12-31 |
| State Street Corp | $6.71M | 4.33% | 63.96M | +1M | +1.78% | 2024-12-31 |
| Primecap Management Co/Ca/ | $3.88M | 2.5% | 36.93M | -896,834 | -2.37% | 2024-12-31 |
| Wellington Management Group Llp | $3.79M | 2.45% | 36.17M | +3M | +10.19% | 2024-12-31 |
| Geode Capital Management, Llc | $3.21M | 2.07% | 30.63M | +1M | +3.52% | 2024-12-31 |
| Capital World Investors | $2.93M | 1.89% | 27.9M | +6M | +28.67% | 2024-12-31 |
| Bank Of America Corp /De/ | $2.88M | 1.86% | 27.48M | -669,930 | -2.38% | 2024-12-31 |
| Jpmorgan Chase & Co | $2.75M | 1.77% | 26.24M | +204,261 | +0.78% | 2024-12-31 |